Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France
Posted on: Tuesday, 3 March 2009, 07:45 CST
100 Percent Purified Seawater Helps Users Breathe Freely
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/afrin/37272/
"Nasal rinsing is a simple technique to cleanse nasal and sinus passages while helping you to breathe freely," said
The sea water in AFRIN PureSea is taken from the Bay of Saint-Malo in
"With consumers becoming more proactive about their health, Schering-Plough recognized the need for a convenient nasal irrigation product that is all-natural and easy to use at home," said Dr.
AFRIN PureSea Nasal Rinse is available in three forms of delivery -- Medium Stream, Gentle Mist, and Ultra-Gentle Mist -- and can be found at most drug stores, mass retailers, and grocery stores nationwide. Both the Medium Stream and Gentle Mist are designed for use in adults and children ages 2 and older, and the Ultra-Gentle Mist is designed for use in children 6 months and older.
About Schering-Plough
Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough, an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in
SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to potential market for AFRIN PureSea. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 1A. "Risk Factors" in Schering-Plough's 2008 10-K, filed
SOURCE Schering-Plough
Source: PR Newswire
Related Articles
- Intervet/Schering-Plough Animal Health Announces Sponsorship Supporting Milk Producers In Malawi
- Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger with Merck
- New Vaccine from Intervet/Schering-Plough Animal Health is First for Canine Influenza Virus
- Schering-Plough Selects Benefit Advocates for Health Advocacy
- Pfizer Animal Health Adds Former Schering-Plough Products to European Portfolio
- Pfizer Animal Health Enters into Agreement to Acquire Animal Health Products From Schering-Plough
- Novacea and Schering-Plough Enter Into Worldwide Development and Commercialization Agreement for Asentar, a Novel Treatment for Prostate Cancer
- Schering-Plough Licenses Rights to Pradefovir
- Schering-Plough Licenses Worldwide Rights to Pradefovir, Oral Hepatitis B Treatment In Development With Valeant Pharmaceuticals and Metabasis Therapeutics
 |
 |
User Comments (0)
RSS Feeds